Novel insights into the mechanism of action of lenalidomide

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02

(2013) X. Leleu et al.   BLOOD

Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance

(2013) Laurence Zitvogel et al.   IMMUNITY

Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro

(2013) C. Mahony et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

(2013) J. Kronke et al.   SCIENCE

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

(2013) G. Lu et al.   SCIENCE

Monitoring NK cell activity in patients with hematological malignancies

(2013) Sébastien Viel et al.   OncoImmunology

Trial Watch: Lenalidomide-based immunochemotherapy

(2013) Michaela Semeraro et al.   OncoImmunology

Trial Watch

(2013) Erika Vacchelli et al.   OncoImmunology

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

(2012) P. G. Richardson et al.   BLOOD

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

(2012) A Lopez-Girona et al.   LEUKEMIA

The secret ally: immunostimulation by anticancer drugs

(2012) Lorenzo Galluzzi et al.   NATURE REVIEWS DRUG DISCOVERY

Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?

(2012) Andy Hsu et al.   OncoImmunology

DKK1 as a novel target for myeloma immunotherapy

(2012) Jianfei Qian et al.   OncoImmunology

High-throughput approaches to discover novel immunomodulatory agents for cancer

(2012) Douglas W. McMillin et al.   OncoImmunology

Trial Watch

(2012) Erika Vacchelli et al.   OncoImmunology

Effector memory regulatory T-cell expansion marks a pivotal point of immune escape in myelodysplastic syndromes

(2012) Adam W. Mailloux et al.   OncoImmunology

IMiD immunomodulatory compounds block C/EBP  translation through eIF4E down-regulation resulting in inhibition of MM

(2011) S. Li et al.   BLOOD

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

(2011) Y. X. Zhu et al.   BLOOD

Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response

(2011) Antonia Lopez-Girona et al.   BRITISH JOURNAL OF HAEMATOLOGY

Teratogenic effects of thalidomide: molecular mechanisms

(2011) Takumi Ito et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Lenalidomide mode of action: linking bench and clinical findings

(2010) Faith Davies et al.   BLOOD REVIEWS

Managing the teratogenic risk of thalidomide and lenalidomide: an industry perspective

(2010) Robert Bwire et al.   Expert Opinion On Drug Safety

Identification of a Primary Target of Thalidomide Teratogenicity

(2010) T. Ito et al.   SCIENCE